News of Note—Dynavax, Emergent BioSolutions and more

In this week's News of Note, Dynavax steadily grew sales of its novel hepatitis B vaccine, Heplisav-B. (Pixabay)

Here is some other vaccine news of note for the week:

> Dynavax’s hepatitis B vaccine Heplisav-B sold $1.3 million in the second quarter, up from $0.2 million in the first quarter. Release

> Emergent BioSolutions posted second-quarter revenue of $220 million, an increase of 118% year over year, thanks to sales of anthrax vaccine BioThrax and smallpox vaccine ACAM2000. Release


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

> Changchun Changsheng Life Sciences, embroiled in China’s latest vaccine scandal, was found to have forged production data for more than four years. Xinhua article

> The International AIDS Vaccine Initiative reached a nonexclusive license agreement with the Public Health Agency of Canada to obtain vesicular stomatitis virus vector technology for a Lassa fever vaccine currently under funding from the Coalition for Epidemic Preparedness Innovations. Release

Suggested Articles

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.